Status:
COMPLETED
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Ajinomoto USA, INC.
Conditions:
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type II
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus under the treatment with pioglitazone
Exclusion
- Patients who cannot follow the diet therapy and/or exercise therapy
- Type 1 diabetes mellitus
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00189774
Last Update
March 13 2008
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Chubu Region, Japan
2
Chugoku Region, Japan
3
Hokkaido Region, Japan
4
Kanto Region, Japan